Corporate Profile

We are a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates that we believe will activate and restore microglial function.

Stock Quote

Minimum 15 minutes delayed. Source:

News Releases
Sep 17, 2024
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Read More
Sep 16, 2024
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
Read More
Aug 29, 2024
Vigil Neuroscience to Present at Upcoming September Investor Conferences
Read More
Events & Presentations
More events are coming soon.
Print Page
Print Page
Email Alerts
Email Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR

Exit

You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?

 

Yes
No